Our quantitative data points are meant to provide a high-level understanding of factors in equity risk models for Heska Corp. Portfolio managers use these models to forecast risk, optimize portfolios and review performance.
We show how HSKA stock compares to 2,000+ US-based stocks, and to peers in the Health Technology sector and Medical Specialties industry.
Please do not consider this data as investment advice. Data is downloaded from sources we deem reliable, but errors may occur.
Heska Corp. engages in the provision of veterinary and animal health diagnostic, and specialty products. It operates through two segments: Core Companion Animal Health and Other Vaccines & Pharmaceuticals. The Core Companion Animal Health segment includes point of care diagnostic laboratory instruments and supplies, imaging instruments, software, and services as well as single use diagnostic and other tests, pharmaceuticals, and vaccines. The Other Vaccines & Pharmaceuticals segment focuses on private label vaccine and pharmaceutical production, primarily for cattle, but also for equine, porcine, avian, feline, and canine. Heska was founded by Robert B. Grieve and Lynnor B. Stevenson in 1988 and is headquartered in Loveland, CO.
Many of the following risk metrics are standardized and transformed into quantitative factors in institutional-level risk models.
Rankings below represent percentiles from 1 to 100, with 1 being the lowest rating of risk.
Stocks with higher beta exhibit higher sensitivity to the ups and downs in the market. (↑↑)
Stocks with higher market capitalization often have lower risk. (↑↓)
Higher average daily dollar volume over the past 30 days implies lower liquidity risk. (↑↓)
Higher price momentum stocks, aka recent winners, equate to lower risk for many investors. (↑↓)
Style risk factors often include measures of profitability and payout levels.
Companies with higher earnings generally provide lower risk. (↑↓)
Companies with higher dividend yields, if sustaintable, are perceived to have lower risk. (↑↓)